New combo aims to free myelofibrosis patients from frequent blood transfusions

NCT ID NCT06517875

Recruiting now Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 study tests whether combining two drugs, momelotinib and luspatercept, can help people with myelofibrosis who need regular blood transfusions. About 68 adults with primary or secondary myelofibrosis will receive the combination orally or by injection. The main goal is to see if they can go at least 12 weeks without needing a transfusion.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: momelotinib and luspatercept
What this could lead to: If successful, this combination could reduce or eliminate the need for regular blood transfusions in people with myelofibrosis, improving their quality of life.
What could go wrong: This is an early phase 2 study with only 68 participants, so results may not apply to everyone. The combination may cause side effects or fail to reduce transfusion needs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS; PRIMARY MYELOFIBROSIS; POST-POLYCYTHEMIA VERA MYELOFIBROSIS; POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELOFIBROSIS; PRIMARY MYELOFIBROSIS; POST-POLYCYTHEMIA VERA MYELOFIBROSIS; POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS PRIMARY MYELOFIBROSIS

Contacts and locations

Locations

GSK Investigational Site
RECRUITING

Ann Arbor, Michigan, 48109, United States
GSK Investigational Site
RECRUITING

New York, New York, 10032, United States
GSK Investigational Site
RECRUITING

Nashville, Tennessee, 37203, United States
GSK Investigational Site
RECRUITING

Houston, Texas, 77030, United States
GSK Investigational Site
RECRUITING

Seattle, Washington, 98109, United States
GSK Investigational Site
RECRUITING

Vancouver, British Columbia, V6Z 1Y6, Canada
GSK Investigational Site
RECRUITING

Toronto, Ontario, M5G 2M9, Canada
GSK Investigational Site
RECRUITING

Montreal, Quebec, H3T 1E2, Canada
GSK Investigational Site
RECRUITING

Montreal, Quebec, H4A 3J1, Canada
GSK Investigational Site
RECRUITING

Angers, 49933, France
GSK Investigational Site
RECRUITING

Brest, 29609, France
GSK Investigational Site
RECRUITING

Lyon, 69004, France
GSK Investigational Site
RECRUITING

Nice, 06202, France
GSK Investigational Site
RECRUITING

Nîmes, 30029, France
GSK Investigational Site
RECRUITING

Paris, 75010, France
GSK Investigational Site
RECRUITING

Poitiers, 86021, France
GSK Investigational Site
RECRUITING

Essen, 45147, Germany
GSK Investigational Site
RECRUITING

Jena, 07747, Germany
GSK Investigational Site
RECRUITING

Lübeck, 23538, Germany
GSK Investigational Site
RECRUITING

Mannheim, 68167, Germany
GSK Investigational Site
RECRUITING

Bologna, 40138, Italy
GSK Investigational Site
RECRUITING

Catania, 95123, Italy
GSK Investigational Site
RECRUITING

Florence, 50134, Italy
GSK Investigational Site
RECRUITING

Meldola FC, 47014, Italy
GSK Investigational Site
RECRUITING

Milan, 20122, Italy
GSK Investigational Site
RECRUITING

Roma, 161, Italy
GSK Investigational Site
RECRUITING

Badalona, 08005, Spain
GSK Investigational Site
RECRUITING

Barcelona, 8035, Spain
GSK Investigational Site
RECRUITING

Las Palmas, 35020, Spain
GSK Investigational Site
RECRUITING

Madrid, 28009, Spain
GSK Investigational Site
RECRUITING

Madrid, 28034, Spain
GSK Investigational Site
RECRUITING

Málaga, 29010, Spain
GSK Investigational Site
RECRUITING

Valencia, 46026, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.